The EU MedTech Innovation Pressure: Navigating 2026 "Crunch" and EY-DG SANTE Findings For years, the European Union was the global launchpad for EU MedTech Innovation, but recent data suggests a pivotal identity crisis is looming. A "CE Mark" was often the first major milestone for a startup before tackling the FDA. However, the tide has turned. As we move deeper into the mid-2020s, the medical technology landscape is facing a pivotal identity crisis. The recent EY-DG SANTE study , commissioned by the European Commission, has provided the data to back up what many MedTech professionals have been whispering in boardrooms: the regulatory burden of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) is creating an "innovation drain." The Data Speaks: Key Findings from the EY-DG SANTE Study The study was designed to monitor the availability of medical devices on the EU market. The results are a wake-up call. According to the ...
GREEN INITIATIVES IN INDIA: Sustainable Practices in Pharma Manufacturing I n an age where environmental concerns are at the forefront of global discussions, every industry must take responsibility for its carbon footprint. The pharmaceutical manufacturing sector, in particular, has been under scrutiny for its environmental impact due to energy-intensive processes and waste generation. However, the industry is increasingly embracing sustainable practices, focusing on green initiatives to reduce its environmental footprint. In this article, we will delve into the world of sustainable pharma manufacturing, with a special focus on green initiatives in India. Green initiatives in India’s pharma manufacturing refer to sustainable practices such as energy efficiency, renewable energy use, water conservation, green chemistry, and waste reduction to minimize environmental impact. Understanding the Need for Green Initiative: The pharmaceutical industry is a vital component of healthcare, ...